摘要
目的探讨沙利度胺联合GP方案治疗晚期乳腺癌的近期疗效及对患者肾功能和血清Th1/Th2细胞因子水平的影响。方法将60例晚期乳腺癌患者按随机数字表法分为对照组和观察组,各30例。对照组:以单独GP方案进行治疗,观察组在此基础上口服沙利度胺。比较2组的疗效、肾功能指标和Th1/Th2细胞因子水平。结果经治疗,观察组总有效率高于对照组(P <0. 05)。2组治疗后的Scr和BUN水平高于且GFR水平低于治疗前(P <0. 05),治疗前后,2组Scr、BUN和Ccr水平差异均无统计学意义(P> 0. 05)。治疗后2组的INF-γ水平和INF-γ/IL-4高于且IL-4水平低于治疗前(P <0. 05),治疗后观察组的INF-γ水平和INF-γ/IL-4高于且IL-4水平低于对照组(P <0. 05)。结论沙利度胺联合GP方案治疗晚期乳腺癌的近期疗效较好,可调节血清Th1/Th2细胞因子水平,纠正Th1/Th2失衡,并且不会明显增加对患者肾功能的损伤,值得临床参考。
Objective To discuss the recent curative effect of thalidomide combined GP Programmed treated in advanced breast cancer and the effect on he renal function and serum Th1/Th2 cytokines levels.Methods A total of 60 advanced breast cancer patients treated were studied and were divided into control group and observation group 30 cases,respectively according to the random number table method.Control group was treated with a single GP regimen,while observation group took the oral thalidomide on that basis.The efficacy,renal function and Th1/Th2 cytokines levels of the two groups were compared.Results After treatment,the total effective rate of observation group were higher than control group(P<0.05).The Scr and BUN levels of two groups after treatment were higher and GFR level was lower than those before treatment(P<0.05),and there was no statistically significant difference between the two groups in Scr,BUN and Ccr levels(P<0.05);After treatment,the Scr and BUN levels of observation group were higher and GFR level was lower than those of control group(P<0.05).Conclusion The curative effect of thalidomide combined GP programme treated in advanced breast cancer is better.It can adjust serum Th1/Th2 cytokines levels,correct Th1/Th2 imbalance,and it does not significantly increase the damagement to renal function,which is worthy of clinical reference.
作者
薛辉
阚炳华
朱宏财
高燕
XUE Hui;KAN Binghua;ZHU Hongcai(Hanzhong Central Hospital,Hanzhong,723000)
出处
《实用癌症杂志》
2018年第12期1953-1955,共3页
The Practical Journal of Cancer
